Clinical Trials Browser

Phase 1 × Magnetic Resonance Spectroscopy × Genitourinary × Clear all

NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Phase 1 Recruiting

Testicular Neoplasms, Seminoma, Hearing Loss

NCT06049576 2026-04-15

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Phase 1 Active not recruiting

Carcinoma, Renal Cell

NCT02496208 2026-04-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT06439836 2026-04-13

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase 1 Recruiting

Carcinoma, Transitional Cell

NCT06982222 2026-04-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Phase 1 Not yet recruiting

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07145177 2026-03-23

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT05245006 2026-03-17

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06305598 2026-02-19

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT04459273 2026-02-05

FAPI PET RDRC

Phase 1 Active not recruiting

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT07219147 2026-01-28

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06105918 2025-12-09

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Phase 1 Active not recruiting

Biochemically Recurrent Prostate Carcinoma

NCT04989959 2025-12-04

[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

Phase 1 Recruiting

Carcinoma, Renal Cell

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Phase 1 Recruiting

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

NCT06942104 2025-07-18

Imaging of Solid Tumors Using 18F-TRX

Phase 1 Recruiting

CNSGenitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Glioma, Neoplasm Metastasis, Prostatic Neoplasms

NCT04457232 2025-07-15

FAPI PET Prost

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04927663 2025-05-20

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

Phase 1 Terminated

2 enrolled 5 charts

Prostatic Neoplasms

NCT02603965 2025-05-02

Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery

Phase 1 Completed

Prostatic Neoplasms

NCT04978675 2024-10-23

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

Phase 1 Completed

Biochemically Recurrent Prostate Carcinoma

NCT06399419 2024-05-30

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Phase 1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Prostatic Neoplasms

NCT04216134 2023-06-15

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Phase 1 Completed

Biochemically Recurrent Prostate Carcinoma

NCT01174199 2022-10-03

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT04279561 2022-09-21

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT01028885 2019-07-25

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Phase 1 Completed

Prostatic Neoplasms

NCT00499135 2017-10-10

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

Phase 1 Completed

Carcinoma, Renal Cell

NCT02429804 2017-05-30

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT01243359 2014-04-02

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Phase 1 Completed

Carcinoma, Renal Cell

NCT00989105 2012-02-28

Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms